A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece

This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcar...

Full description

Bibliographic Details
Main Authors:	Nikolaos Nomikos, Christos Eleftheriou, Kostas Athanasakis
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Toxins
Subjects:	cost-effectiveness analysis budget impact analysis abobotulinumtoxinA limb spasticity
Online Access:	https://www.mdpi.com/2072-6651/15/9/561

Similar Items

Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment
by: Jörg Wissel, et al.
Published: (2020-02-01)

Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom
by: Muthukumar M, et al.
Published: (2017-04-01)

Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
by: Raymond L Rosales, et al.
Published: (2018-06-01)

Post Hoc Subgroup Analysis of the BCause Study Assessing the Effect of AbobotulinumtoxinA on Post-Stroke Shoulder Pain in Adults
by: Marcelo Riberto, et al.
Published: (2022-11-01)

Modelling Long-Term Outcomes and Risk of Death for Patients with Post-Stroke Spasticity Receiving Abobotulinumtoxina Treatment and Rehabilitation Therapy
by: Klemens Fheodoroff, et al.
Published: (2022-08-01)

Long-term follow-up of intravesical abobotulinumtoxinA (Dysport®) injections in women with idiopathic detrusor overactivity
by: Mohammad Sajjad Rahnama'i, et al.
Published: (2024-01-01)

Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies
by: Alberto Esquenazi, et al.
Published: (2020-09-01)

Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review
by: Alfonso Fasano, et al.
Published: (2020-07-01)

Intradermal Micro-Dosing of AbobotulinumtoxinA for Face-Lifting: How Long Does It Last?
by: Rungsima Wanitphakdeedecha, et al.
Published: (2020-06-01)

AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients
by: Malgorzata Field, et al.
Published: (2018-12-01)

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
by: Mark F. Lew, et al.
Published: (2021-01-01)

Use of AbobotulinumtoxinA for Cosmetic Treatments in the Neck, and Middle and Lower Areas of the Face: A Systematic Review
by: Hassan Galadari, et al.
Published: (2021-02-01)

Muscle Selection and Dosing in a Phase 3, Pivotal Study of AbobotulinumtoxinA Injection in Upper Limb Muscles in Children With Cerebral Palsy
by: Joyce Oleszek, et al.
Published: (2021-10-01)

Effect of early use of AbobotulinumtoxinA after stroke on spasticity progression: Protocol for a randomised controlled pilot study in adult subjects with moderate to severe upper limb spasticity (ONTIME pilot)
by: Keng He Kong, et al.
Published: (2017-06-01)

Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: A retrospective safety and efficacy evaluation
by: Nigar Dursun, et al.
Published: (2019-04-01)

Goal Attainment after Treatment with Abobotulinumtoxina and a Tailored Home Therapy Programme in Children with Upper Limb Spasticity: Descriptive, Exploratory Analysis of a Large Randomized, Controlled Study
by: Jorge Carranza-del Río, et al.
Published: (2022-12-01)

A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity
by: Clive Bezzina, et al.
Published: (2023-08-01)

Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study
by: Alberto Esquenazi, et al.
Published: (2023-10-01)

Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity
by: Kaku M, et al.
Published: (2016-03-01)

Comparative study of the effect of abobotulinumtoxin A and rehabilitation in the treatment of spastic equine foot of the cerebral palsy child walking
by: Bakhta CHARANE, et al.
Published: (2022-05-01)

The safety of botulinum neurotoxin type A's intraarticular application in experimental animals
by: Ana Dugonjić Okroša, et al.
Published: (2023-06-01)

Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins
by: Travis J.W. Hassell, et al.
Published: (2020-04-01)

Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?
by: Joely Kaufman-Janette, et al.
Published: (2021-07-01)

Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation
by: Carolina Gorodetsky, et al.
Published: (2021-07-01)

Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
by: Fraint A, et al.
Published: (2016-02-01)

AbobotulinumtoxinA Doses in Upper and Lower Limb Spasticity: A Systematic Literature Review
by: Alexis Schnitzler, et al.
Published: (2022-10-01)

Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational Data
by: François Giuliano, et al.
Published: (2023-06-01)

Continuation of Long-Term Care for Cervical Dystonia at an Academic Movement Disorders Clinic
by: David Charles, et al.
Published: (2013-04-01)

Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
by: Amélie Huynh Le Maux, et al.
Published: (2015-12-01)

Abobotulinumtoxina injections in shoulder muscles to improve adult upper limb spasticity: Results from a phase 4 real-world study and a phase 3 open-label trial
by: Thierry Lejeune, et al.
Published: (2020-06-01)

Hemifacial spasm responsive to single low-dose abobotulinumtoxin A in a patient with relapsing-remitting multiple sclerosis: A case report
by: Julie Ann Kristy L Torres, et al.
Published: (2022-01-01)

AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis
by: Abogunrin S, et al.
Published: (2015-09-01)

A symptomatic approach to tuberculosis screening for high-risk groups in Malaysia: Cost-effectiveness and budget impact analysis
by: Nor Zam Azihan Mohd Hassan, et al.
Published: (2022-12-01)

HIV partner services in Kenya: a cost and budget impact analysis study
by: Peter Cherutich, et al.
Published: (2018-09-01)

Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment with a cholinesterase inhibitor and memantine in Switzerland
by: Alena M. Pfeil, et al.
Published: (2012-11-01)

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
by: Kongsaengdao S, et al.
Published: (2018-04-01)

Cost utility, budget impact, and scenario analysis of racecadotril in addition to oral rehydration for acute diarrhea in children in Malaysia
by: Rautenberg TA, et al.
Published: (2018-03-01)

Cost-Utility Analysis of Incobotulinumtoxin-A Compared With Conventional Therapy in the Management of Post-Stroke Spasticity in Romania
by: Adina Turcu-Stiolica, et al.
Published: (2020-01-01)

Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion
by: Pedram Sendi, et al.
Published: (2021-10-01)

Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life
by: Benucci M, et al.
Published: (2019-06-01)